Abstract: Objective: To compare the curative and adverse effects of gemcitabine or gemzar plus oxaliplatin (GEMOX) and gemcitabine alone in biweekly chemotherapeutic regimens in patients with advanced pancreatic cancer. Methods: Thirty patients with advanced pancreatic cancer were chosen during a period from November 2003 to January 2005 to receive the biweekly GEMOX regimen, i.e., gemcitabine 1000 mg/m² infusion on day 1 followed by oxaliplatin 100 mg/m² on day 2, with a cycle of every 2 weeks (group A). At the same time, another 30 patients from the same time period were randomly chosen to receive gemcitabine alone, i.e., 1000 mg/m² infusion on day 1, 8 and 15, once a week, with a cycle of every 4 weeks (group B). The difference between the curative and adverse effects of the two regimens was compared. Results: The response rate of patients in group A was as follows: partial remission (PR) occurred in 3/30 cases (10%), no change (NC) in 21/30 (70%) and progression of disease (PD) in 6/30 (20%). A 1-year survival time was found in 5 patients (16.67%). The response of patients in group B was that PR was seen in 1/30 cases (3.33%), NC in 14/30 (46.7%) and PD in 15/30 (50%). Three patients remained alive after 1 year (10.0%). The major adverse effects of chemotherapy were nausea, vomiting, myelosuppression and peripheral neurotoxicity. Conclusion: The biweekly combined chemotherapeutic regimen has a slight advantage over the single gemzar regimen when comparing the inhibition of disease progression and prolonging of the survival time. However, the adverse effects of the two treatments are almost the same, so the biweekly regimen is recommended for clinical application.